Who Exports Actinomycin from India — 184 Suppliers Behind a $2.9M Market
India's actinomycin export market is supplied by 184 active exporters who collectively shipped $2.9M across 933 shipments. EUGIA PHARMA SPECIALITIES LIMITED leads with a 61.4% market share, followed by MYLAN LABORATORIES LIMITED and IKRIS PHARMA NETWORK PRIVATE LIMITED. The top 5 suppliers together control 81.1% of total export value, reflecting a concentrated market structure.
Top Actinomycin Exporters from India — Ranked by Export Value
EUGIA PHARMA SPECIALITIES LIMITED is the leading actinomycin exporter from India, holding a 61.4% share of the $2.9M market across 933 shipments from 184 exporters. The top 5 suppliers — EUGIA PHARMA SPECIALITIES LIMITED, MYLAN LABORATORIES LIMITED, IKRIS PHARMA NETWORK PRIVATE LIMITED, CELON LABORATORIES PRIVATE LIMITED, GNH INDIA PHARMACEUTICALS LIMITED — collectively control 81.1% of total export value, indicating a highly concentrated market. Individual shares are: EUGIA PHARMA SPECIALITIES LIMITED (61.4%), MYLAN LABORATORIES LIMITED (11.9%), IKRIS PHARMA NETWORK PRIVATE LIMITED (3.7%), CELON LABORATORIES PRIVATE LIMITED (2.3%), GNH INDIA PHARMACEUTICALS LIMITED (1.8%).
Top Actinomycin Exporters from India
Ranked by export value · 184 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | EUGIA PHARMA SPECIALITIES LIMITED DACTINOMYCIN FOR INJECTION 0.5 MG/VIAL )DACILON 0.5 MG DACTINOMYCIN INJDACILON 0.5 DACTINOMYCIN INJ. | $1.8M | 1 | 61.4% |
| 2 | MYLAN LABORATORIES LIMITED | $348.8K | 1 | 11.9% |
| 3 | IKRIS PHARMA NETWORK PRIVATE LIMITED DACILON 0.5 MG DACTINOMYCIN USP./0.5MG(BDACILON 0.5 | $108.1K | 1 | 3.7% |
| 4 | CELON LABORATORIES PRIVATE LIMITED | $67.3K | 10 | 2.3% |
| 5 | GNH INDIA PHARMACEUTICALS LIMITED DACILON 0.5 MG DACTINOMYCIN USP./0.5MG(BDACILON 0.5 | $53.4K | 4 | 1.8% |
| 6 | VAMA LIFECARE PRIVATE LIMITED DACILON 0.5 MG DACTINOMYCIN USP./0.5MG(BDACILON 0.5DACTINOMYCIN FOR INJECTION USP 0.5 MG | $44.7K | 5 | 1.5% |
| 7 | VENUS REMEDIES LIMITED DACTINOMYCIN FOR INJECTION USP 0.5 MG/5MDACTINOVA | $35.6K | 4 | 1.2% |
| 8 | ZUVIUS LIFESCIENCES PRIVATE LIMITED DACTINOMYCIN 0.5MG INJ DACTINOZ 0.5MG IDACTINOMYCIN INJECTION USP 0 5MG VIALDACTINOMYCIN 0.5MG INJ ,PACK-1 VIALVLS | $34.5K | 4 | 1.2% |
| 9 | FLORENCIA HEALTHCARE | $22.1K | 3 | 0.8% |
| 10 | GETWELL PHARMA INDIA PRIVATE LIMITED TINOWEL 0.5 MGTINOWEL 0 5MG DACTINOMYCIN FOR INJECTION USPTINOWEL 0.5 MG (DACTINOMYCIN FOR INJECTI | $19.8K | 5 | 0.7% |
| 11 | CHANDRA BHAGAT PHARMA LIMITED DACTINOMYCIN INJECTION 0.5MG DADACIHAL 0.5MG INJ. DACTINOMYCIN INJECTIDACILON 0.5MG DACTINOMYCIN INJECTION 0.5MG VIAL | $19.2K | 4 | 0.7% |
| 12 | UNITED BIOTECH PRIVATE LIMITED TINOWEL 0.5 MGTINOWEL 0 5MG DACTINOMYCIN FOR INJECTION USPTINOWEL 0.5 MG (DACTINOMYCIN FOR INJECTI | $14.9K | 4 | 0.5% |
| 13 | SEVATTO PHARMA DACTINOMYCIN FOR INJ 0.5MG/VIAL.. BATCH | $13.3K | 1 | 0.5% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Actinomycin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| EUGIA PHARMA SPECIALITIES LIMITED | Warning Letter, August 20 | Unknown | Unknown | 179 | Received FDA warning letter for CGMP violations; also holds 179 ANDA approvals. |
| MYLAN LABORATORIES LIMITED | Warning Letter, December | Unknown | Unknown | Unknown | Received FDA warning letter for CGMP violations at Indore facility. |
| GLENMARK PHARMACEUTICALS LIMITED | Warning Letter, July 2025 | Unknown | Unknown | Unknown | Received FDA warning letter for CGMP violations at Pithampur facility. |
TransData Nexus reviewed the regulatory standing of 3 leading Actinomycin exporters from India. 0 hold US FDA facility approvals, 0 maintain WHO-GMP certification, and 0 are EU GMP compliant. 3 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Actinomycin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for active pharmaceutical ingredients (APIs) and bulk drug manufacturing. The city hosts over 800 pharmaceutical companies, including major players like Dr. Reddy's Laboratories and Aurobindo Pharma. The presence of Genome Valley, India's first biotech cluster, underscores Hyderabad's emphasis on research and development in pharmaceuticals.
The city's robust infrastructure, skilled workforce, and supportive government policies have made it a preferred destination for API production. This positions Hyderabad as a strategic location for sourcing Actinomycin, given its capacity for large-scale API manufacturing.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations and finished dosage forms. Gujarat contributes nearly 28% of India's pharmaceutical production, with Ahmedabad and Vadodara being central to this output. The region is home to prominent companies such as Zydus Cadila and Torrent Pharmaceuticals.
The well-established chemical industry in this area provides a strong foundation for pharmaceutical manufacturing. The proximity to major ports facilitates efficient export logistics, making it an advantageous location for the production and export of Actinomycin formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a significant export gateway for pharmaceuticals. Mumbai, being India's financial capital, hosts the headquarters of several pharmaceutical giants, including Cipla and Sun Pharma. The region's advanced infrastructure and proximity to major ports like Nhava Sheva enhance its export capabilities.
The concentration of corporate offices, regulatory bodies, and research institutions in this area fosters a conducive environment for pharmaceutical exports. This makes the Mumbai-Thane-Raigad corridor a strategic point for distributing Actinomycin to international markets.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing zone, largely due to favorable tax incentives and government policies. The region hosts over 1,000 pharmaceutical units, including major companies like Dr. Reddy's and Cipla.
The tax benefits and cost-effective manufacturing environment have attracted numerous pharmaceutical manufacturers to Baddi-Nalagarh. This makes it a viable option for producing cost-sensitive drugs like Actinomycin.
5Sourcing Recommendations
- Diversify Supplier Base: Given that EUGIA PHARMA SPECIALITIES LIMITED accounts for 61.4% of Actinomycin exports, it's advisable to diversify the supplier base to mitigate risks associated with over-reliance on a single supplier.
- Leverage Hyderabad's API Strength: Utilize Hyderabad's robust API manufacturing capabilities to source high-quality Actinomycin, ensuring consistency and compliance with international standards.
- Utilize Gujarat's Formulation Expertise: Engage with manufacturers in the Ahmedabad-Vadodara region for the production of Actinomycin formulations, benefiting from their established infrastructure and proximity to export ports.
- Optimize Export Logistics via Mumbai: Coordinate with suppliers in the Mumbai-Thane-Raigad corridor to streamline export processes, taking advantage of the region's advanced logistics and port facilities.
By strategically engaging with these pharmaceutical clusters, TransData Nexus can enhance its supply chain resilience and optimize the sourcing and distribution of Actinomycin.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Actinomycin exporters from India
EUGIA PHARMA SPECIALITIES LIMITED — Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride Injection
Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Vancomycin Hydrochloride for Injection USP, 1.25 g/vial and 1.5 g/vial, Single-Dose Vial. - IMPACT: This approval may enhance Eugia Pharma's market presence, potentially influencing its Actinomycin export capabilities.
Impact: This approval may enhance Eugia Pharma's market presence, potentially influencing its Actinomycin export capabilities.
Common Questions — Actinomycin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which actinomycin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, EUGIA PHARMA SPECIALITIES LIMITED leads with 5 recorded shipments worth $1.8M. MYLAN LABORATORIES LIMITED (4 shipments) and IKRIS PHARMA NETWORK PRIVATE LIMITED (103 shipments) are also established high-volume exporters.
Q How many actinomycin manufacturers are there in India?
India has 184 active actinomycin exporters with a combined export market of $2.9M across 933 shipments to 97 countries. The top 5 suppliers hold 81.1% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for actinomycin from India?
Average FOB unit price: $14.44 per unit, ranging from $0.13 to $501.53. Average shipment value: $3.1K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 184 verified Indian exporters of Actinomycin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 933 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 97 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
933 Verified Shipments
184 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists